Valuation: Kadimastem Ltd

Market Cap 53.23M 18.01M 15.55M 14.62M 13.29M 24.99M 1.72B 25.4M 171M 66.96M 862M 67.61M 66.15M 2.87B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 53.23M 18.01M 15.55M 14.62M 13.29M 24.99M 1.72B 25.4M 171M 66.96M 862M 67.61M 66.15M 2.87B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
31.94%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-2.83% - - 19.38M
-1.78%-1.68%+1.99%+13.84% 49.24B
+0.85%-0.70%+465.55%+579.03% 43.3B
-2.40%-0.23%+12.20%+70.22% 40.48B
-2.01%-0.85%+24.95%+7.51% 39.75B
-0.50%+0.85%+20.60%+49.65% 32.67B
-0.59%-2.06%+26.13%+117.79% 16.24B
+0.38%-3.23% - - 16.23B
+0.49%+0.92%+4.32%+22.16% 14.04B
-0.43%+4.70%+79.75%+29.11% 13.43B
Average -0.49%+0.49%+79.44%+111.17% 29.49B
Weighted average by Cap. -0.93%+0.60%+96.21%+132.98%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem Ltd
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
-